Humacyte (HUMA) Q2 FY26 earnings call

Humacyte reported a transformative quarter driven by breakthrough Phase 3 results for its ATEV in female dialysis patients, significantly outperforming standard of care and paving the way for a planned sBLA filing in November. The company also initiated a commercial rebuild for Symbest in vascular injury, showing early signs of increased adoption and laying groundwork for future dialysis access launch. Pipeline progress continued with FDA acceptance of the CTEV IND for CABG, positioning the company for growth across multiple indications.